Mometason Cipla (Mometasone Furoate)

Mometasone furoate activates glucocorticoid receptors in the cells lining the nasal mucosa. This activation suppresses the production of inflammatory cytokines and mediators, leading to reduced swelling, mucus production and irritation within the nose.

The specific dose and frequency of Mometason are determined by the prescribing clinician based on the patient’s age, severity of symptoms and treatment response. Patients should follow the prescriber’s instructions and not alter the regimen on their own.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against risks before prescribing it to pregnant or nursing mothers, and patients should discuss any concerns with their doctor.

To request Mometason, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Mometason (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic absorption profile, similar to other agents such as fluticasone propionate. Clinical choice often depends on physician preference, patient response and formulary considerations.

Store Mometason at room temperature, below 25 °C. Keep the spray in its original packaging, protect it from moisture, direct sunlight and extreme heat to maintain product stability.

Mometason is delivered as a metered‑dose nasal spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, closes the opposite nostril, and sprays the prescribed number of sprays while breathing in gently.

Serious but rare risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal mucosa.

Mometason should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, and it should be used with caution in patients who have recent nasal surgery, severe nasal trauma, or uncontrolled systemic infections.